Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Platelets induce apoptosis during sepsis in a contact-dependent manner that is inhibited by GPIIb/IIIa blockade.

Sharron M, Hoptay CE, Wiles AA, Garvin LM, Geha M, Benton AS, Nagaraju K, Freishtat RJ.

PLoS One. 2012;7(7):e41549. doi: 10.1371/journal.pone.0041549. Epub 2012 Jul 26.

2.

Sepsis alters the megakaryocyte-platelet transcriptional axis resulting in granzyme B-mediated lymphotoxicity.

Freishtat RJ, Natale J, Benton AS, Cohen J, Sharron M, Wiles AA, Ngor WM, Mojgani B, Bradbury M, Degnan A, Sachdeva R, Debiase LM, Ghimbovschi S, Chow M, Bunag C, Kristosturyan E, Hoffman EP.

Am J Respir Crit Care Med. 2009 Mar 15;179(6):467-73. doi: 10.1164/rccm.200807-1085OC. Epub 2009 Jan 8.

3.

Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.

Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.

Thromb Haemost. 2000 Jun;83(6):915-22.

PMID:
10896249
4.
5.

P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.

Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL 3rd.

J Am Heart Assoc. 2013 May 15;2(3):e000026. doi: 10.1161/JAHA.113.000026.

6.

Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.

Guth BD, Seewaldt-Becker E, Himmelsbach F, Weisenberger H, Müller TH.

J Cardiovasc Pharmacol. 1997 Aug;30(2):261-72.

PMID:
9269956
7.

Hypothermia-induced platelet aggregation: no effect of aprotinin (trasylol) but inhibition by eptifibatide (integrilin).

Straub A, Azevedo R, Beierlein W, Wendel HP, Scheule AM, Ziemer G.

Thorac Cardiovasc Surg. 2005 Apr;53(2):80-4.

PMID:
15786005
8.

Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.

Nakada MT, Sassoli PM, Tam SH, Nedelman MA, Jordan RE, Kereiakes DJ.

J Thromb Thrombolysis. 2002 Aug;14(1):15-24.

PMID:
12652146
9.
10.
11.
12.

Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI.

Puri A, Bansal A, Narain VS, Sethi R, Dwivedi SK, Puri VK, Saran RK.

Indian Heart J. 2013 Mar-Apr;65(2):152-7. doi: 10.1016/j.ihj.2012.08.007. Epub 2012 Aug 27.

13.

Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.

Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, Fitzgerald D, Bode C, Peter K.

Circ Res. 2006 Jul 7;99(1):25-33. Epub 2006 Jun 15.

14.

Human neutrophil alpha-defensins induce formation of fibrinogen and thrombospondin-1 amyloid-like structures and activate platelets via glycoprotein IIb/IIIa.

Horn M, Bertling A, Brodde MF, Müller A, Roth J, Van Aken H, Jurk K, Heilmann C, Peters G, Kehrel BE.

J Thromb Haemost. 2012 Apr;10(4):647-61. doi: 10.1111/j.1538-7836.2012.04640.x.

15.

Use of antiplatelet agents in sepsis: a glimpse into the future.

Akinosoglou K, Alexopoulos D.

Thromb Res. 2014 Feb;133(2):131-8. doi: 10.1016/j.thromres.2013.07.002. Epub 2013 Oct 6. Review.

PMID:
24103487
16.
17.

Activation of tumour cell ECM degradation by thrombin-activated platelet membranes: potentially a P-selectin and GPIIb/IIIa-dependent process.

Pang JH, Coupland LA, Freeman C, Chong BH, Parish CR.

Clin Exp Metastasis. 2015 Jun;32(5):495-505. doi: 10.1007/s10585-015-9722-5. Epub 2015 May 16.

PMID:
25982688
18.

Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.

Pontiggia L, Steiner B, Ulrichts H, Deckmyn H, Forestier M, Beer JH.

Thromb Haemost. 2006 Dec;96(6):774-80.

PMID:
17139372
19.

Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.

Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D.

Circulation. 1999 May 4;99(17):2231-8.

20.

Supplemental Content

Support Center